Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling.

Maity PC, Bilal M, Koning MT, Young M, van Bergen CAM, Renna V, Nicolò A, Datta M, Gentner-Göbel E, Barendse RS, Somers SF, de Groen RAL, Vermaat JSP, Steinbrecher D, Schneider C, Tausch E, Bittolo T, Bomben R, Mazzarello AN, Del Poeta G, Kroes WGM, van Wezel JT, Imkeller K, Busse CE, Degano M, Bakchoul T, Schulz AR, Mei H, Ghia P, Kotta K, Stamatopoulos K, Wardemann H, Zucchetto A, Chiorazzi N, Gattei V, Stilgenbauer S, Veelken H, Jumaa H.

Proc Natl Acad Sci U S A. 2020 Feb 11. pii: 201913810. doi: 10.1073/pnas.1913810117. [Epub ahead of print]

2.

Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.

Roex MCJ, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld SAJ, Hoogstraten C, van Liempt E, Zwaginga JJ, de Wreede LC, Meij P, Vossen ACTM, Danhof S, Einsele H, Schaafsma MR, Veelken H, Halkes CJM, Jedema I, Falkenburg JHF.

Leukemia. 2019 Oct 17. doi: 10.1038/s41375-019-0600-z. [Epub ahead of print]

PMID:
31624377
3.

Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT.

Styczynski J, Tridello G, Gil L, Ljungman P, Mikulska M, Ward KN, Cordonnier C, de la Camara R, Averbuch D, Knelange N, Socié G, Chevallier P, Blaise D, Yakoub-Agha I, Forcade E, Cornelissen J, Maertens J, Petersen E, Nguyen-Quoc S, Veelken H, Schaap N, Passweg J, Michallet M, Fegueux N, Deconinck E, Russell N, Basak G, Bader P, Montoto S, Kröger N, Cesaro S; Infectious Diseases Working Party EBMT.

Bone Marrow Transplant. 2019 Dec;54(12):2060-2071. doi: 10.1038/s41409-019-0627-9. Epub 2019 Jul 30.

PMID:
31363166
4.

Peripheral IgE Repertoires of Healthy Donors Carry Moderate Mutation Loads and Do Not Overlap With Other Isotypes.

Koning MT, Trollmann IJM, van Bergen CAM, Alvarez Saravia D, Navarrete MA, Kiełbasa SM, Veelken H.

Front Immunol. 2019 Jul 3;10:1543. doi: 10.3389/fimmu.2019.01543. eCollection 2019.

5.

Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft.

Loeff FC, van Egmond EHM, Moes DJAR, Wijnands C, Von Dem Borne PA, Veelken H, Falkenburg JHF, Jedema I, Halkes CJM.

Transpl Immunol. 2019 Dec;57:101209. doi: 10.1016/j.trim.2019.06.001. Epub 2019 Jun 14.

6.

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.

Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Berenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST.

Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020.

7.

Acquired N-Linked Glycosylation Motifs in B-Cell Receptors of Primary Cutaneous B-Cell Lymphoma and the Normal B-Cell Repertoire.

Koning MT, Quinten E, Zoutman WH, Kiełbasa SM, Mei H, van Bergen CAM, Jansen P, Vergroesen RD, Willemze R, Vermeer MH, Tensen CP, Veelken H.

J Invest Dermatol. 2019 Oct;139(10):2195-2203. doi: 10.1016/j.jid.2019.04.005. Epub 2019 Apr 28.

PMID:
31042459
8.

MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity.

Huijbers MG, Vergoossen DL, Fillié-Grijpma YE, van Es IE, Koning MT, Slot LM, Veelken H, Plomp JJ, van der Maarel SM, Verschuuren JJ.

Neurol Neuroimmunol Neuroinflamm. 2019 Feb 21;6(3):e547. doi: 10.1212/NXI.0000000000000547. eCollection 2019 May.

9.

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M.

J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14.

10.

Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting.

Bondanza A, Ruggeri L, Noviello M, Eikema DJ, Bonini C, Chabannon C, van der Werf S, van Biezen A, de Wreede LC, Crucitti L, Vago L, Merluzzi M, Massei MS, Veelken H, Koc Y, Bader P, Gruhn B, Locatelli F, Ciceri F, Toubert A, Velardi A; EBMT Cell Therapy and Immunobiology Working Party.

Bone Marrow Transplant. 2019 Jun;54(6):867-876. doi: 10.1038/s41409-018-0351-x. Epub 2018 Dec 7.

PMID:
30531916
11.

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT.

Schmid C, Labopin M, Schaap N, Veelken H, Schleuning M, Stadler M, Finke J, Hurst E, Baron F, Ringden O, Bug G, Blaise D, Tischer J, Bloor A, Esteve J, Giebel S, Savani B, Gorin NC, Ciceri F, Mohty M, Nagler A; EBMT Acute Leukaemia Working Party.

Br J Haematol. 2019 Mar;184(5):782-787. doi: 10.1111/bjh.15691. Epub 2018 Nov 22.

PMID:
30467839
12.

Idelalisib.

Zirlik K, Veelken H.

Recent Results Cancer Res. 2018;212:243-264. doi: 10.1007/978-3-319-91439-8_12. Review.

PMID:
30069634
13.

High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.

Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP.

Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7. No abstract available.

PMID:
29514783
14.

High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor-/CD52- T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell-Depleted Allogeneic Stem Cell Transplantation.

Loeff FC, Falkenburg JHF, Hageman L, Huisman W, Veld SAJ, van Egmond HME, van de Meent M, von dem Borne PA, Veelken H, Halkes CJM, Jedema I.

J Immunol. 2018 Mar 15;200(6):2199-2208. doi: 10.4049/jimmunol.1701018. Epub 2018 Feb 2.

15.

Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT.

Roth-Guepin G, Canaani J, Ruggeri A, Labopin M, Finke J, Cornelissen JJ, Delage J, Stuhler G, Rovira M, Potter M, Stadler M, Veelken H, Cahn JY, Collin M, Beguin Y, Giebel S, Nagler A, Mohty M.

Oncotarget. 2017 Dec 4;8(68):112972-112979. doi: 10.18632/oncotarget.22934. eCollection 2017 Dec 22.

16.

Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria.

Hayashi H, Ruggeri A, Volt F, Cornelissen JJ, Socié G, Sengeloev H, Michallet M, Karakasis D, Petersen E, Cahn JY, Veelken H, Mercier M, Rohrlich PS, Rafii H, Kenzey C, Xavier E, Duarte RF, Basak GW, Rocha V, Gluckman E; Eurocord and the Complications and Quality of Life WP of EBMT.

Bone Marrow Transplant. 2018 Apr;53(4):417-421. doi: 10.1038/s41409-017-0061-9. Epub 2018 Jan 12. No abstract available.

PMID:
29330402
17.

Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.

Oosten LEM, Chamuleau MED, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK, Smeekes OS, Kersten MJ, Hardi L, Baars JW, Demandt AMP, Stevens WBC, Nijland M, van Imhoff GW, Brouwer R, Uyl-de Groot CA, Kluin PM, de Jong D, Veelken H.

Ann Hematol. 2018 Feb;97(2):255-266. doi: 10.1007/s00277-017-3167-7. Epub 2017 Dec 6.

18.

Distribution and clinical determinants of time-to-positivity of blood cultures in patients with neutropenia.

Lambregts MMC, Warreman EB, Bernards AT, Veelken H, von dem Borne PA, Dekkers OM, Visser LG, de Boer MG.

Eur J Haematol. 2018 Feb;100(2):206-214. doi: 10.1111/ejh.13001. Epub 2017 Dec 13.

PMID:
29171916
19.

Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.

Simon-Gabriel CP, Foerster K, Saleem S, Bleckmann D, Benkisser-Petersen M, Thornton N, Umezawa K, Decker S, Burger M, Veelken H, Claus R, Dierks C, Duyster J, Zirlik K.

Haematologica. 2018 Jan;103(1):136-147. doi: 10.3324/haematol.2017.165381. Epub 2017 Nov 9.

20.

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation.

Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakoub-Agha I, Mufti G, Rovira M, Arnold R, de Witte T, Robin M, Kröger N.

Haematologica. 2018 Feb;103(2):237-245. doi: 10.3324/haematol.2017.168716. Epub 2017 Nov 3.

21.

Donor T-cell responses and disease progression patterns of multiple myeloma.

Eefting M, de Wreede LC, Von dem Borne PA, Halkes CJM, Kersting S, Marijt EWA, Putter H, Veelken H, Schetelig J, Falkenburg JHF.

Bone Marrow Transplant. 2017 Dec;52(12):1609-1615. doi: 10.1038/bmt.2017.201. Epub 2017 Oct 2.

PMID:
28967897
22.

B-cell receptor sequencing of anti-citrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N-glycosylation sites during somatic hypermutation.

Vergroesen RD, Slot LM, Hafkenscheid L, Koning MT, van der Voort EIH, Grooff CA, Zervakis G, Veelken H, Huizinga TWJ, Rispens T, Scherer HU, Toes REM.

Ann Rheum Dis. 2018 Jun;77(6):956-958. doi: 10.1136/annrheumdis-2017-212052. Epub 2017 Aug 23. No abstract available.

PMID:
28835463
23.

Long-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin.

van der Hem JGK, de Wreede LC, Brand A, Veelken H, Falkenburg JHF, Halkes CJM.

Haematologica. 2017 Oct;102(10):e382-e383. doi: 10.3324/haematol.2017.171215. Epub 2017 Jul 13. No abstract available.

24.

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Onida F, de Wreede LC, van Biezen A, Eikema DJ, Byrne JL, Iori AP, Schots R, Jungova A, Schetelig J, Finke J, Veelken H, Johansson JE, Craddock C, Stelljes M, Theobald M, Holler E, Schanz U, Schaap N, Bittenbring J, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2017 Jun;177(5):759-765. doi: 10.1111/bjh.14619. Epub 2017 Mar 28.

PMID:
28369779
25.

Germline mutations predisposing to diffuse large B-cell lymphoma.

Leeksma OC, de Miranda NF, Veelken H.

Blood Cancer J. 2017 Mar 10;7(3):e541. doi: 10.1038/bcj.2017.22. No abstract available.

26.

Germline mutations predisposing to diffuse large B-cell lymphoma.

Leeksma OC, de Miranda NF, Veelken H.

Blood Cancer J. 2017 Feb 17;7(2):e532. doi: 10.1038/bcj.2017.15. Review. Erratum in: Blood Cancer J. 2017 Mar 10;7(3):e541.

27.

Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.

van Bergen CA, van Luxemburg-Heijs SA, de Wreede LC, Eefting M, von dem Borne PA, van Balen P, Heemskerk MH, Mulder A, Claas FH, Navarrete MA, Honders WM, Rutten CE, Veelken H, Jedema I, Halkes CJ, Griffioen M, Falkenburg JH.

J Clin Invest. 2017 Feb 1;127(2):517-529. doi: 10.1172/JCI86175. Epub 2017 Jan 9.

28.

Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.

Benkisser-Petersen M, Buchner M, Dörffel A, Dühren-von-Minden M, Claus R, Kläsener K, Leberecht K, Burger M, Dierks C, Jumaa H, Malavasi F, Reth M, Veelken H, Duyster J, Zirlik K.

PLoS One. 2016 Dec 30;11(12):e0169159. doi: 10.1371/journal.pone.0169159. eCollection 2016.

29.

Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.

Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, Bunjes D, Schaap N, Vigouroux S, Bacigalupo A, Veelken H, Sierra J, Eder M, Niederwieser D, Mohty M, Nagler A.

J Hematol Oncol. 2016 Nov 8;9(1):118.

30.

ARTISAN PCR: rapid identification of full-length immunoglobulin rearrangements without primer binding bias.

Koning MT, Kiełbasa SM, Boersma V, Buermans HPJ, van der Zeeuw SAJ, van Bergen CAM, Cleven AHG, Kluin PM, Griffioen M, Navarrete MA, Veelken H.

Br J Haematol. 2017 Sep;178(6):983-986. doi: 10.1111/bjh.14180. Epub 2016 Jun 15. No abstract available.

PMID:
27301611
31.

Effectivity of a strategy in elderly AML patients to reach allogeneic stem cell transplantation using intensive chemotherapy: Long-term survival is dependent on complete remission after first induction therapy.

von dem Borne PA, de Wreede LC, Halkes CJ, Marijt WA, Falkenburg JH, Veelken H.

Leuk Res. 2016 Jul;46:45-50. doi: 10.1016/j.leukres.2016.03.010. Epub 2016 Apr 9.

32.

Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation.

Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S, Ward KN, Cordonnier C, Einsele H, Socie G, Milpied N, Veelken H, Chevallier P, Yakoub-Agha I, Maertens J, Blaise D, Cornelissen J, Michallet M, Daguindau E, Petersen E, Passweg J, Greinix H, Duarte RF, Kröger N, Dreger P, Mohty M, Nagler A, Cesaro S.

J Clin Oncol. 2016 Jul 1;34(19):2212-20. doi: 10.1200/JCO.2015.64.2405. Epub 2016 Apr 18.

PMID:
27091716
33.

Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion.

Eefting M, de Wreede LC, Halkes CJ, von dem Borne PA, Kersting S, Marijt EW, Veelken H, Putter H, Schetelig J, Falkenburg JH.

Haematologica. 2016 Apr;101(4):506-14. doi: 10.3324/haematol.2015.136846. Epub 2016 Jan 22.

34.

Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment.

Chevalier N, Mueller M, Mougiakakos D, Ihorst G, Marks R, Schmitt-Graeff A, Veelken H.

Leuk Lymphoma. 2016 Sep;57(9):2150-60. doi: 10.3109/10428194.2015.1135432. Epub 2016 Jan 12. Erratum in: Leuk Lymphoma. 2016 Sep;57(9):I.

PMID:
26757600
35.

Selection patterns of B-cell receptors and the natural history of follicular lymphoma.

Scherer F, van der Burgt M, Kiełbasa SM, Bertinetti-Lapatki C, Dühren von Minden M, Mikesch K, Zirlik K, de Wreede L, Veelken H, Navarrete MA.

Br J Haematol. 2016 Dec;175(5):972-975. doi: 10.1111/bjh.13901. Epub 2015 Dec 21. No abstract available.

PMID:
26687432
36.

Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.

Penack O, Tridello G, Hoek J, Socié G, Blaise D, Passweg J, Chevallier P, Craddock C, Milpied N, Veelken H, Maertens J, Ljungman P, Cornelissen J, Thiebaut-Bertrand A, Lioure B, Michallet M, Iacobelli S, Nagler A, Mohty M, Cesaro S.

Bone Marrow Transplant. 2016 Mar;51(3):418-23. doi: 10.1038/bmt.2015.237. Epub 2015 Oct 26.

PMID:
26501769
37.

Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Socie G, Kroeger N, Blaise D, Veelken H, Bermudez A, Or R, Lioure B, Beelen D, Fegueux N, Hamladji RM, Nagler A, Mohty M.

Leuk Res. 2015 Sep;39(9):933-7. doi: 10.1016/j.leukres.2015.04.009. Epub 2015 Apr 24.

PMID:
26003666
38.

Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire.

Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen JJ, Andersen NS, Maillard N, Nguyen S, Blaise D, Deconinck E, Veelken H, Milpied N, Van Gelder M, Peffault de Latour R, Gluckman E, Kröger N, Schetelig J, Rocha V.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1515-23. doi: 10.1016/j.bbmt.2015.04.026. Epub 2015 May 7.

39.

High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation.

Fox CP, Boumendil A, Schmitz N, Finel H, Luan JJ, Sucak G, Blaise D, Finke J, Pflüger KH, Veelken H, Gorin NC, Poiré X, Ganser A, Dreger P, Sureda A.

Leuk Lymphoma. 2015;56(12):3295-300. doi: 10.3109/10428194.2015.1037764. Epub 2015 Aug 26.

PMID:
25899403
40.

Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation.

Scherer F, Navarrete MA, Bertinetti-Lapatki C, Boehm J, Schmitt-Graeff A, Veelken H.

Leuk Lymphoma. 2016;57(1):151-60. doi: 10.3109/10428194.2015.1037758. Epub 2015 May 18.

PMID:
25860234
41.

Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Eder S, Labopin M, Arcese W, Or R, Majolino I, Bacigalupo A, de Rosa G, Volin L, Beelen D, Veelken H, Schaap NP, Kuball J, Cornelissen J, Nagler A, Mohty M; Acute Leukemia Working Party.

Eur J Haematol. 2016 Jan;96(1):90-7. doi: 10.1111/ejh.12553. Epub 2015 Apr 21.

PMID:
25807864
42.

Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma.

Schneider D, Dühren-von Minden M, Alkhatib A, Setz C, van Bergen CA, Benkißer-Petersen M, Wilhelm I, Villringer S, Krysov S, Packham G, Zirlik K, Römer W, Buske C, Stevenson FK, Veelken H, Jumaa H.

Blood. 2015 May 21;125(21):3287-96. doi: 10.1182/blood-2014-11-609404. Epub 2015 Mar 17.

43.

Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors.

Zhu D, Bhatt S, Lu X, Guo F, Veelken H, Hsu DK, Liu FT, Alvarez Cubela S, Kunkalla K, Vega F, Chapman-Fredricks JR, Lossos IS.

Leukemia. 2015 Jul;29(7):1587-99. doi: 10.1038/leu.2015.39. Epub 2015 Feb 13.

PMID:
25676418
44.

Evidence for idiotype-directed immunosurveillance is restricted to follicular lymphoma and attributable to somatic hypermutation.

Papaioannou D, Strothmeyer AM, Dühren-von Minden M, Keppler-Hafkemeyer A, Zirlik K, Mikesch K, van Bergen CA, Navarrete MA, Veelken H.

Haematologica. 2015 Apr;100(4):e143-6. doi: 10.3324/haematol.2014.111252. Epub 2015 Jan 23. No abstract available.

45.

Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.

Tucunduva L, Ruggeri A, Sanz G, Furst S, Cornelissen J, Linkesch W, Mannone L, Ribera JM, Veelken H, Yakoub-Agha I, González Valentín ME, Schots R, Arcese W, Montesinos P, Labopin M, Gluckman E, Mohty M, Rocha V.

Br J Haematol. 2014 Sep;166(5):749-57. doi: 10.1111/bjh.12970. Epub 2014 Jun 25.

PMID:
24961645
46.

Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT.

Czerw T, Labopin M, Gorin NC, Giebel S, Blaise D, Dumas PY, Foa R, Attal M, Schaap N, Michallet M, Bonmati C, Veelken H, Mohty M.

Bone Marrow Transplant. 2014 Jul;49(7):950-4. doi: 10.1038/bmt.2014.64. Epub 2014 Apr 7.

PMID:
24710564
47.

PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).

Decker S, Finter J, Forde AJ, Kissel S, Schwaller J, Mack TS, Kuhn A, Gray N, Follo M, Jumaa H, Burger M, Zirlik K, Pfeifer D, Miduturu CV, Eibel H, Veelken H, Dierks C.

Mol Cancer Ther. 2014 May;13(5):1231-45. doi: 10.1158/1535-7163.MCT-13-0575-T. Epub 2014 Mar 21.

48.

Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation.

Eefting M, von dem Borne PA, de Wreede LC, Halkes CJ, Kersting S, Marijt EW, Veelken H, Falkenburg JF.

Haematologica. 2014 Apr;99(4):751-8. doi: 10.3324/haematol.2013.089565. Epub 2013 Nov 15.

49.

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.

Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M.

J Clin Oncol. 2013 Oct 1;31(28):3549-56. doi: 10.1200/JCO.2013.48.8114. Epub 2013 Aug 26.

PMID:
23980086
50.

Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL.

Eefting M, Halkes CJ, de Wreede LC, van Pelt CM, Kersting S, Marijt EW, von dem Borne PA, Willemze R, Veelken H, Falkenburg JH.

Bone Marrow Transplant. 2014 Feb;49(2):287-91. doi: 10.1038/bmt.2013.111. Epub 2013 Aug 12. Erratum in: Bone Marrow Transplant. 2014 Feb;49(2):320.

PMID:
23933760

Supplemental Content

Loading ...
Support Center